Fundamentally disagree. Innovation is about finding better solutions to outstanding problems. Sometimes risk is unavoidable but there is constant pressure to mitigate or avoid risk.
Money on vaccines, in theory, is money well spent. Not so much when the vaccines rely on novel MOA and novel deep freeze supply chains...
Zip, The big irony in all this is that pure EPA could end up as an "adjunct" drug for most any cancer therapy. High blood EPA levels are very beneficial and appear to be a key factor in getting better health outcomes in every area studied in that manner. Why not cancer? Because I am cynical (and realistic) it may be because BP cannot make much money on it. Cancer & rare disease drugs seem to be priced as if the sky is the limit. Cheap, yet effective drugs such as EPA and Vitamin D-3 are ignored. Why has no researcher come up with the idea as simple as: "Hey, why don't we do a cancer therapy study with one arm using 4 or 5 grams of pure EPA and see if it enhances results?"